Wave Life Sciences Ltd. (WVE) Stock Price, Financials & Summary

Price chart

Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21

Key dataOct 21, 2026

Open$3.42

From 52W high−84.19%

Volume2.17M

Market cap$664.66M

P/E (TTM)—

P/S (TTM)10.2x

Div yield—

Key dataOct 21, 2026

Open

$3.42

From 52W high

−84.19%

Volume

2.17M

Market cap

$664.66M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.1x

P/E (TTM)

—

RSI (14)

37.7

MomentumView details →

1D Return

−1.46%

YTD Return

−80.03%

SummaryUpdated Jun 1, 2026

Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage genetic medicine company founded in 2012 and based in Singapore. The company specializes in developing novel stereopure oligonucleotides through its proprietary PRISM discovery and drug development platform. Wave went public in November 2015 and has since established itself as a pioneer in the field of RNA-targeted therapeutics, with a particular focus on rare genetic diseases and common conditions like obesity. The company has built strategic partnerships with major pharmaceutical companies including Pfizer, Takeda, and GlaxoSmithKline to advance its innovative therapeutic approaches.

Ask drillr about Wave Life Sciences Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.1x

EV/Sales

3.3x

P/S (TTM)

10.2x

P/B (TTM)

1.5x

ProfitabilityView details →

Gross Margin

96.54%

Net Margin

−309.73%

EBITDA Margin

−302.09%

ROE (TTM)

−44.64%

ROA (TTM)

−36.26%

Asset Turnover

0.11x

GrowthView details →

Revenue YoY

−30.42%

EPS YoY

−22.47%

FCF YoY

+6.93%

Revenue CAGR 3Y

+127.08%

EPS CAGR 3Y

−72.86%

EBITDA YoY

−52.35%

MomentumView details →

1D Return

−1.46%

YTD Return

−80.03%

1Y Return

−52.72%

RSI (14)

37.7

vs 50D SMA

−21.46%

vs 200D SMA

−56.55%

Capital & dividendView details →

Debt/Equity

0.10x

Current Ratio

9.99x

Quick Ratio

9.99x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.34

EPS Surprise

−13.43%

Beats (12Q)

6/12

Next Q EPS Est

−$0.33

Avg Surprise (4Q)

8.51%

Rev Surprise

−69.50%

Financials snapshotView financials →

Revenue (TTM)

65.37M

Net Income (TTM)

−202.47M

Op. CF (TTM)

−184.68M

Next earningsOct 27, 2026 →

Latest newsMore news →

Wave Life Sciences Ltd. announced that it will host a webcast and conference call on October 27, 2026, to review its third-quarter financial results and provide business updates.2d ago

Wave Life Sciences Ltd. announced that it will host a virtual Research Day on November 4, 2026, at 9:30 a.m. ET.3d ago

Similar companies

Aura Biosciences, Inc.AURA Achieve Life Sciences, Inc.ACHV Design Therapeutics, Inc.DSGN Avalo Therapeutics, Inc.AVTX Brii Biosciences Limited02137.HK Ginkgo Bioworks Holdings, Inc.DNA Find similar companies →

Latest newsMore news →

Wave Life Sciences Ltd. announced that it will host a webcast and conference call on October 27, 2026, to review its third-quarter financial results and provide business updates.2d ago Wave Life Sciences Ltd. announced that it will host a virtual Research Day on November 4, 2026, at 9:30 a.m. ET.3d ago